Extended Half Life Factor (EHF) Products For Heavy Menstrual Bleeding in Hemophilia Carriers
Status:
Completed
Trial end date:
2019-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this feasibility study is to find out if two clotting factor products,
Eloctate [hemophilia A] and Alprolix [hemophilia B], can reduce the amount of menstrual
bleeding in female hemophilia A and B carriers (14 years of age or older) who have severe or
heavy bleeding. These products are FDA-approved for use in males with hemophilia A and B to
prevent and treat bleeding. They are not approved specifically to reduce menstrual bleeding,
but may be useful for this purpose. Both products have an "extended half life" which means
they circulate in the body longer than other FVIII or FIX products. The study team will
gather additional information about the safety of these drugs and how well they work. The
results of this feasibility study will provide information for an upcoming larger study.